S 6 117th Congress Senate Health

Biosimilar Red Tape Elimination Act

Introduced: November 17, 2022 Introduced by: Lee, Mike Republican · Utah See on congress.gov

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Nov 17, 2022

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Nov 17, 2022

Introduced in Senate

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Plain-English summary Congressional Research Service

Biosimilar Red Tape Elimination Act

This bill removes and otherwise modifies certain requirements related to the approval of biosimilars, such as prohibiting the Food and Drug Administration from requiring studies that assess the risks of switching between the biosimilar and the reference biologic.

What's happening now November 17, 2022

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Bill text 1 version

Introduced in Senate Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 1

Health, Education, Labor, and Pensions Committee
Senate

Cite this page click to expand

APA

U.S. Congress. (2026). S. 6: Biosimilar Red Tape Elimination Act. 117th Congress. Open America. https://openamerica.io/bill/117-S-6/

MLA

"S. 6: Biosimilar Red Tape Elimination Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-6/.

Bluebook (legal)

S. 6, 117th Cong. (2026), https://openamerica.io/bill/117-S-6/.

Markdown link

[S. 6: Biosimilar Red Tape Elimination Act](https://openamerica.io/bill/117-S-6/)